210 related articles for article (PubMed ID: 30760869)
21. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Lam SSY; Leung AYH
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
[TBL] [Abstract][Full Text] [Related]
22. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
Xu J; Zhang Y; Hu J; Ren Y; Wang H
Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
[No Abstract] [Full Text] [Related]
24. Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review.
Zafar N; Ghias K; Fadoo Z
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e135-e141. PubMed ID: 32573082
[TBL] [Abstract][Full Text] [Related]
25. Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.
Krizsán S; Péterffy B; Egyed B; Nagy T; Sebestyén E; Hegyi LL; Jakab Z; Erdélyi DJ; Müller J; Péter G; Csanádi K; Kállay K; Kriván G; Barna G; Bedics G; Haltrich I; Ottóffy G; Csernus K; Vojcek Á; Tiszlavicz LG; Gábor KM; Kelemen Á; Hauser P; Gaál Z; Szegedi I; Ujfalusi A; Kajtár B; Kiss C; Matolcsy A; Tímár B; Kovács G; Alpár D; Bödör C
J Mol Diagn; 2023 Aug; 25(8):555-568. PubMed ID: 37088137
[TBL] [Abstract][Full Text] [Related]
26. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
27. [Identification of novel pathogenic gene mutations in pediatric acute myeloid leukemia by whole-exome resequencing].
Shiba N
Rinsho Ketsueki; 2015 Dec; 56(12):2419-25. PubMed ID: 26725349
[TBL] [Abstract][Full Text] [Related]
28. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
[TBL] [Abstract][Full Text] [Related]
29. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
[TBL] [Abstract][Full Text] [Related]
30. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
31. [Genetic characteristics and clinical outcomes of pediatric acute myeloid leukemia with NUP98-NSD1 fusion gene].
Wang T; Ni JB; Wang XY; Dai Y; Ma XL; Su YC; Gao YY; Chen X; Yuan LL; Liu HX
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2820-2825. PubMed ID: 31550809
[No Abstract] [Full Text] [Related]
32. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
[TBL] [Abstract][Full Text] [Related]
34. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
Asghari H; Talati C
Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
[TBL] [Abstract][Full Text] [Related]
35. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
36. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
37. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
38. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
39. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
[TBL] [Abstract][Full Text] [Related]
40. Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia.
Nakamura H; Inokuchi K; Yamaguchi H; Dan K
J Nippon Med Sch; 2004 Aug; 71(4):270-8. PubMed ID: 15329487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
